Report copyright - ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS · Venclyxto monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation
Please pass captcha verification before submit form